Atea Pharmaceuticals (AVIR) Accumulated Expenses (2019 - 2026)

Atea Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 20.15% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 20.15% YoY), while the FY2025 annual figure was $6.4 million, up 9.04% from the prior year.
• Accumulated Expenses was $2.3 million for Q1 2026 at Atea Pharmaceuticals, down from $6.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $20.4 million in Q2 2024 to a low of $1.9 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $9.7 million across 5 years, with a median of $6.4 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses slumped 91.53% in 2022, then soared 471.11% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $15.2 million in 2022, then tumbled by 62.54% to $5.7 million in 2023, then grew by 3.65% to $5.9 million in 2024, then advanced by 9.04% to $6.4 million in 2025, then plunged by 64.68% to $2.3 million in 2026.
• The last three Accumulated Expenses figures came in at $2.3 million (Q1 2026), $6.4 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.